This is one of the pioneering studies in the literature showing that SGLT2 inhibitors may have a potential benefit in reducing or preventing the development of CIN and is, to our knowledge, the first study with an isolated NST-ACS patient population [20,21,22]. This evidence concerns the gene SLC5A2 and cervical squamous intraepithelial neoplasia.